[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Magrath I: Lessons from clinical trials in African Burkitt lymphoma. Curr Opin Oncol; 2009 Sep;21(5):462-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons from clinical trials in African Burkitt lymphoma.
  • PURPOSE OF REVIEW: The center of gravity of the AIDS epidemic has moved - in 2007, 67% of all persons living with HIV infection and 72% of all deaths from AIDS occurred in Africa.
  • The present review focuses on the treatment of an AIDS-defining malignancy, Burkitt lymphoma, since the discovery of the tumor in 1958 to provide a backdrop to the increasing necessity of dealing with AIDS-associated Burkitt lymphoma in Africa.
  • RECENT FINDINGS: In Africa, it appears that AIDS-associated Burkitt lymphoma is increasing, but although treatment outcome is presently poor, the demonstration that highly active antiretroviral therapy permits the same treatment results to those in AIDS-unassociated Burkitt lymphoma provides hope for the future.
  • SUMMARY: In the 1960s, the extraordinary response of Burkitt lymphoma to chemotherapy provided considerable encouragement to pioneer oncologists.
  • Within little more than a decade, the most active drugs, the value of combination chemotherapy, and the need for intrathecal treatment, as well as the risk of tumor lysis syndrome had been demonstrated, providing a platform on which further advances could be made in resource-rich countries.
  • The impact of the HIV epidemic on the epidemiology and treatment of African Burkitt lymphoma will receive increasing focus in the coming years.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620863.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 64
  •  go-up   go-down


2. Chao C, Xu L, Abrams D, Leyden W, Horberg M, Towner W, Klein D, Tang B, Silverberg M: Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS; 2010 Jul 17;24(11):1765-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy.
  • OBJECTIVE: To investigate the survival outcomes for non-Hodgkin lymphoma (NHL) in HIV-infected vs. uninfected patients from the same integrated healthcare system, and to identify prognostic factors for HIV-related NHL in the era of combined antiretroviral therapy.
  • Two-year all-cause and lymphoma-specific mortality by HIV status were examined using multivariable Poisson regression.
  • Among HIV-infected patients, prognostic factors of demographics, lymphoma, and HIV-related characteristics for the same outcomes were also examined.
  • Fifty-nine percent of HIV-infected patients died within 2 years after NHL diagnosis as compared with 30% of HIV-uninfected patients.
  • HIV status was independently associated with a doubling of 2-year all-cause mortality (relative risk = 2.0, 95% confidence interval 1.7-2.3).
  • This elevated mortality risk for HIV-infected patients was similar for all race groups, lymphoma stages, and histologic subtypes.
  • HIV-infected patients with CD4 cell count below 200 cells/microl, prior AIDS-defining illness, or both were also at increased risk for lymphoma-specific mortality as compared with HIV-uninfected patients.
  • Among HIV-infected NHL patients, significant prognostic factors for overall mortality included prior AIDS-defining illness and Burkitt's subtype.
  • Better management and therapeutic approaches to extend survival time for HIV-related NHL are needed.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • [Cites] AIDS Read. 2004 Nov;14(11):605-17 [15570672.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] Leuk Lymphoma. 2001 Mar;41(1-2):105-16 [11342362.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):237-42 [11860669.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Aug 15;30(5):478-84 [12154338.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Clin Infect Dis. 2003 Dec 1;37(11):1556-64 [14614680.001]
  • [Cites] Clin Infect Dis. 2004 Jan 1;38(1):142-4 [14679461.001]
  • [Cites] Am J Epidemiol. 2004 Aug 15;160(4):301-5 [15286014.001]
  • [Cites] HIV Med. 2004 Sep;5(5):377-84 [15369514.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2943-6 [15238428.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8477-82 [16230675.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73 [17117144.001]
  • [Cites] Antivir Ther. 2007;12(6):931-9 [17926647.001]
  • [Cites] Lancet. 2009 Apr 18;373(9672):1352-63 [19361855.001]
  • [Cites] AIDS. 2009 Nov 13;23(17):2337-45 [19741479.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):155-63 [11148572.001]
  • (PMID = 20453630.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA134234-01; United States / NIAID NIH HHS / AI / AI071725-01A1; United States / NIAID NIH HHS / AI / K01 AI071725; United States / NCI NIH HHS / CA / R01 CA134234-01; United States / NIAID NIH HHS / AI / K01 AI071725-01A1; United States / NCI NIH HHS / CA / R01CA134234; United States / NIAID NIH HHS / AI / K01AI071725; United States / NCI NIH HHS / CA / R01 CA134234
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Other-IDs] NLM/ NIHMS198983; NLM/ PMC2895006
  •  go-up   go-down


3. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM: AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol; 2005 Jul 1;23(19):4430-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
  • PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras.
  • PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83).
  • RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis.
  • Compared with HIV-BL, HIV-DLCL was associated with significantly lower CD4 counts in the pre-HAART but not the HAART era.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Burkitt Lymphoma / mortality. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leucovorin / therapeutic use. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Methotrexate / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use


Advertisement
4. Okano M: The evolving therapeutic approaches for Epstein-Barr virus infection in immunocompetent and immunocompromised individuals. Curr Drug Targets Immune Endocr Metabol Disord; 2003 Jun;3(2):137-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, in immunocompetent individuals only symptomatic treatment is recommended, although fatal or malignant diseases such as fatal IM, Burkitt's lymphoma (BL) and nasopharyngeal carcinoma (NPC) may develop without obvious preceding immunodeficiency.
  • However, in certain circumstances such as in patients with hereditary immunodeficiencies, in recipients receiving a potent immunosuppressant or in patients with acquired immunodeficiency syndrome (AIDS), this virus strongly links to the development of lethal lymphoproliferative diseases (LPD).
  • These LPD range from IM-like illness associated with polyclonal proliferation to malignant lymphoma in monoclonal fashion.
  • To date, no specific therapy has been available for latent EBV infection itself, but understanding the underlying pathogenetic mechanisms in each condition provides the possible treatment including anti-viral agents, immune modulators and chemotherapeutic drugs.
  • Furthermore, severe combined immunodeficiency (SCID) mouse engrafted with human peripheral blood mononuclear cells is a suitable model for EBV-associated LPD which occur in human beings.
  • This concise review focuses on recent understanding of the pathogenetic mechanisms in various EBV-associated diseases in immunocompetent and immunocompromised individuals, and discusses potent therapeutic approaches in each condition.
  • [MeSH-major] Epstein-Barr Virus Infections / drug therapy. Immunocompetence / drug effects. Immunocompromised Host / drug effects
  • [MeSH-minor] Animals. Disease Models, Animal. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12769785.001).
  • [ISSN] 1568-0088
  • [Journal-full-title] Current drug targets. Immune, endocrine and metabolic disorders
  • [ISO-abbreviation] Curr. Drug Targets Immune Endocr. Metabol. Disord.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 33
  •  go-up   go-down


5. Ghez D, Oksenhendler E, Scieux C, Lassoued K: Haemorrhagic cystitis associated with adenovirus in a patient with AIDS treated for a non-Hodgkin's lymphoma. Am J Hematol; 2000 Jan;63(1):32-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haemorrhagic cystitis associated with adenovirus in a patient with AIDS treated for a non-Hodgkin's lymphoma.
  • Adenovirus-induced haemorrhagic cystitis has been reported chiefly in bone marrow or kidney transplant recipients.
  • We report here on an HIV-positive patient treated for a Burkitt's lymphoma who developed gross haematuria associated with fever and burning urination.
  • Usual causes of haematuria were ruled out: lithiasis, urinary tract lesions, glomerulonephritis, mycobacterium and schistosoma infections, and drug toxicity.
  • In conclusion, adenovirus should be considered as a potential cause of haemorrhagic cystitis in AIDS patients whose immunosuppression is aggravated by cytotoxic drugs.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Adenoviridae Infections / complications. Burkitt Lymphoma / complications. Cystitis / virology. Lymphoma, AIDS-Related / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10602165.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


6. Astrow AB, Tarabay G, Salerno VE, Cook WA, Lin R, Lascher S, Li Z, Mazumder A, Halperin I, Cho J, Jaffar Z, McLaughlin M, Blum RH, Kempin SJ: Long-term survival in patients with human immunodeficiency virus-associated small non-cleaved cell lymphoma: the role for short course intensive chemotherapy. Hematol Oncol; 2003 Sep;21(3):131-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in patients with human immunodeficiency virus-associated small non-cleaved cell lymphoma: the role for short course intensive chemotherapy.
  • While intensive chemotherapy is recommended for the treatment of non-HIV related adult small non-cleaved lymphoma (SNCL), including Burkitt's and Burkitt-like lymphoma, optimal treatment for patients with HIV-associated SNCL is not known.
  • Of this cohort 39% were complete responders (CR) and 36% were long-term lymphoma-free survivors.
  • Short course intensive chemotherapy (McMaster) was administered to 23 patients; 17 received less intensive conventional combination chemotherapy; and four received single-agent chemotherapy or no treatment.
  • In advanced disease, McMaster chemotherapy was found to be associated with substantial early mortality but was curative in a significant number of patients.
  • [MeSH-major] Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / virology. Cohort Studies. Female. Humans. Male. Middle Aged. Registries. Remission Induction. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Small non-cleaved cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 John Wiley & Sons, Ltd.
  • (PMID = 14579241.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. De Paoli P: Novel virally targeted therapies of EBV-associated tumors. Curr Cancer Drug Targets; 2008 Nov;8(7):591-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel virally targeted therapies of EBV-associated tumors.
  • EBV is associated to the development of several malignancies of lymphoid and epithelial origin, including Burkitt's Lymphoma, post-transplant lymphoproliferative disorders, Hodgkin's disease, AIDS-associated lymphomas, NK/T cell lymphoma and Nasopharyngeal carcinoma.
  • EBV genes play an essential role in the development of the malignant phenotype and therefore molecules interfering with the function of these genes may represent an essential tool to treat EBV-associated malignancies.
  • [MeSH-major] Antiviral Agents / administration & dosage. Drug Delivery Systems / trends. Epstein-Barr Virus Infections / drug therapy. Herpesvirus 4, Human / drug effects. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Humans. Immunotherapy, Adoptive / methods. Immunotherapy, Adoptive / trends

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991568.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 122
  •  go-up   go-down


8. Straus DJ: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma. Recent Results Cancer Res; 2002;159:143-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma.
  • Chemotherapy regimens similar to those used for non-Hodgkin's lymphoma (NHL) not associated with human immunodeficiency virus (HIV) infection have been used for patients with HIV-associated NHL with less success.
  • In univariate and multivariate analyses of 21 pretreatment features of patients in this trial, four factors emerged as adversely prognostic with respect to survival: age >35 years, intravenous drug use, CD4 counts < 100/mm3 and stage III/IV disease.
  • A recent trial of the AIDS Malignancy Consortium found that low-dose chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone: CHOP) and standard-dose chemotherapy had similar response rates, acceptable toxicity and minimal alterations in cyclophosphamide, doxorubicin and indinavir pharmacokinetics in HIV-associated lymphoma patients also on HAART (stavudine, lamivudine and indinavir).
  • There is a suggestion that Burkitt-type lymphomas may tend to occur in HIV-infected patients with relatively well preserved immune function and CD4 cell counts.
  • Recent results from our institution suggest that similar outcomes are achievable with intensive chemotherapy in patients with Burkitt's lymphomas with or without HIV infection.
  • With improved immune status and improved bone marrow function with the use of HAART, it will probably become more possible to treat many patients with aggressive HIV-associated NHL with more intensive treatment regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11785838.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


9. Wulff EA, Simpson DM: Peripheral neuropathy associated with acquired immunodeficiency syndrome (AIDS)-related Burkitt's lymphoma. Muscle Nerve; 2000 Nov;23(11):1764-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral neuropathy associated with acquired immunodeficiency syndrome (AIDS)-related Burkitt's lymphoma.
  • Peripheral neuropathy associated with acquired immunodeficiency syndrome (AIDS)-related Burkitt's lymphoma usually occurs as a toxic effect of chemotherapeutic agents.
  • Whereas primary peripheral nerve involvement is an unusual complication, we report on a human immunodeficiency virus (HIV)-positive patient with Burkitt's lymphoma and sciatic neuropathy due to compression by a lymphomatous mass.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Burkitt Lymphoma / complications. Lymphoma, AIDS-Related / complications. Nerve Compression Syndromes / etiology


10. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM: Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol; 2000 Oct;111(1):239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies.
  • Cell-free Epstein-Barr virus (EBV) DNA has recently been detected in the plasma and serum of patients with Hodgkin's disease, post-transplant lymphoproliferative disease (PTLD) and acquired immunodeficiency syndrome-related lymphoma.
  • However, no data are available on the temporal variation of plasma/serum EBV DNA levels in patients with EBV-associated lymphoid malignancies during the course of therapy.
  • Using a real-time quantitative polymerase chain reaction assay, we studied the plasma EBV DNA levels in 13 patients with EBV-associated lymphoid malignancies (six patients with Hodgkin's disease, four with nasal natural killer/T-cell lymphoma, two cases of PTLD and one patient with Burkitt's lymphoma) at presentation and during therapy.
  • The EBV status in tumour cells was also examined in 12 of these patients using in situ hybridization for EBV-encoded small RNAs (EBERs).
  • All patients who responded to therapy demonstrated a significant reduction of plasma EBV DNA to low or undetectable levels, whereas in two patients with ineffective therapy, disease progression was associated with a rapid increase in plasma EBV DNA levels.
  • We concluded that plasma EBV DNA is detectable in a wide range of EBV-associated lymphoid malignancies.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antiviral Agents / therapeutic use. Case-Control Studies. Disease Progression. Female. Follow-Up Studies. Humans. In Situ Hybridization. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / virology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / virology. Lymphoproliferative Disorders / drug therapy. Lymphoproliferative Disorders / virology. Male. Middle Aged. Polymerase Chain Reaction / methods. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11091207.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral
  •  go-up   go-down


11. Lan K, Murakami M, Bajaj B, Kaul R, He Z, Gan R, Feldman M, Robertson ES: Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther; 2009 Nov;8(22):2136-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a common cancer in AIDS patients closely associated with Kaposi's sarcoma-associated herpesvirus (KSHV).
  • Previously, we showed that KSHV latency associated nuclear antigen (LANA) stabilizes intracellular activated Notch1 (ICN) involved in maintenance of the malignant phenotype of KSHV infected PEL cells in vitro.
  • The gamma-secretase inhibitor (GSI) which specifically blocks the production of ICN slows down the proliferation of the KSHV infected PEL cell lines BCBL1, BC3 as well as JSC1 in vitro.
  • We observed that the onset of tumorigenesis of KSHV infected PELs was significantly delayed in GSI treated SCID mice harboring the PEL cell lines.
  • We also found that GSI treatment resulted in necrosis as well as apoptosis in tumors generated by the xenotransplanted KSHV positive PEL cell lines.
  • In contrast, GSI had no effect on mice harboring BJAB cells, a KSHV negative Burkitt's lymphoma cell line where ICN levels were negligible.
  • Our study provides further evidence to suggest that targeted downregulation of abnormal Notch signaling has therapeutic potential for KSHV related primary effusion lymphomas.
  • [MeSH-major] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Dipeptides / therapeutic use. Herpesviridae Infections. Herpesvirus 8, Human / pathogenicity. Lymphoma, Primary Effusion / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Receptor, Notch1 / antagonists & inhibitors. Tumor Virus Infections
  • [MeSH-minor] Animals. Antigens, Viral / physiology. Apoptosis. Burkitt Lymphoma / pathology. Cell Line, Tumor / transplantation. Herpesvirus 4, Human / isolation & purification. Herpesvirus 4, Human / pathogenicity. Mice. Mice, Inbred NOD. Mice, SCID. Necrosis. Nuclear Proteins / physiology. Random Allocation. Signal Transduction / drug effects. Specific Pathogen-Free Organisms. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Nov;8(22):2144-6 [20068386.001]
  • (PMID = 19783901.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / PHS HHS / / A1067037; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / CA108461; United States / NIDCR NIH HHS / DE / DE017338
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Dipeptides; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Neoplasm Proteins; 0 / Notch1 protein, mouse; 0 / Nuclear Proteins; 0 / Receptor, Notch1; 0 / latency-associated nuclear antigen; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


12. Lehmann C, Wyen C, Hoffmann C, Fätkenheuer G: Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma. HIV Med; 2005 Jan;6(1):51-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma.
  • Treatment of AIDS-related malignant lymphoma (ARL) remains a therapeutic challenge.
  • We report the case of a 38-year-old man with advanced HIV-1 infection, pulmonary tuberculosis and Burkitt's lymphoma.
  • Six months later, the patient achieved not only a complete remission of Burkitt's lymphoma and sustained viral suppression, but also a full recovery from tuberculosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Antitubercular Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / drug therapy. Adult. Humans. Male. Tuberculosis, Pulmonary / complications. Tuberculosis, Pulmonary / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670254.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


13. Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC: Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma.
  • BACKGROUND: Strategies to circumvent or lessen the myelotoxicity associated with combination chemotherapy may improve the overall outcome of the management of patients particularly in resource poor settings.
  • OBJECTIVES: To develop effective non-myelotoxic therapies for Burkitt's Lymphoma (BL) and AIDS-related non-Hodgkin's lymphoma.
  • DATA EXTRACTION: A systematic review of the clinical problem of combination chemotherapy.
  • DATA SYNTHESIS: Review of published experience with some of these strategies including dose-modification of multi-agent chemotherapy; rationale for targeted therapies, and the preclinical development of a mouse model exploring the role of metronomic scheduling substantiate pragmatism and feasibility of these approaches.
  • CONCLUSION: Myelotoxic death rates using multi-agent induction chemotherapy approach 25% for endemic Burkitt's lymphoma and range between 20% to 60% for AIDS-related malignancy.
  • Investigations and alternative approaches that lessen or circumvent myelotoxicity of traditional cytotoxic chemotherapy for the management of Burkitt's lymphoma and AIDS-related non-Hodgkin's lymphoma in the resource-constrained setting are warranted.
  • This can be achieved by developing targeted anti-viral and other strategies, such as the use of bryostatin 1 and vincristine, and by developing a preclinical mouse model to frame the clinical rationale for a pilot trial of metronomic therapy for the treatment of Burkitt's and AIDS-related lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy. Macrolides / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Bryostatins. Drug Therapy, Combination. Humans

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619692.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine
  • [Number-of-references] 38
  •  go-up   go-down


14. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Kantarjian H: Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer; 2002 Mar 1;94(5):1492-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
  • BACKGROUND: Patients with acquired immunodeficiency syndrome (AIDS)-associated lymphoma/leukemia have a poor prognosis and are frequently treated with low-intensity therapy.
  • The authors investigated the feasibility and efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive chemotherapy regimen, in patients with AIDS-associated Burkitt lymphoma/leukemia, as well as the possible impact of highly active antiretroviral therapy (HAART) in these patients.
  • METHODS: Thirteen patients with AIDS-associated Burkitt lymphoma (six patients) or leukemia (acute lymphoblastic leukemia; seven patients) were treated with hyper-CVAD alternating with high-dose methotrexate and ara-C for a total of eight cycles.
  • Nine patients were diagnosed with human immunodeficiency virus (HIV) infection at the time of diagnosis of Burkitt lymphoma/leukemia; the other 4 patients had been diagnosed with HIV infection for a median of 37 months (range, 18-137) prior to the diagnosis of Burkitt lymphoma/leukemia.
  • RESULTS: Twelve patients (92%) achieved a complete remission (CR) and one achieved a partial response (PR).
  • The regimen was universally myelosuppressive, but the toxicity profiles, recoveries from myelosuppression, and incidences of infectious complications were similar to that of non-HIV patients with Burkitt lymphoma/leukemia treated with the same regimen.
  • CONCLUSIONS: Hyper-CVAD is an effective regimen for patients with AIDS-associated Burkitt lymphoma/leukemia, with acceptable toxicity.
  • The combination of hyper-CVAD and HAART is associated with long-term survival in patients with the two diseases, which, until recently, were both considered invariably fatal and almost futile to treat medically.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Survival Analysis. Thrombocytopenia / chemically induced. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920506.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


15. Spina M, Gloghini A, Tirelli U, Carbone A: Therapeutic options for HIV-associated lymphomas. Expert Opin Pharmacother; 2010 Oct;11(15):2471-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic options for HIV-associated lymphomas.
  • IMPORTANCE OF THE FIELD: The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population.
  • AREAS COVERED IN THIS REVIEW: This review summarizes reports from 1995 to the present which focus on the treatment strategies and their prognostic relevance in the setting of HIV-associated lymphomas.
  • WHAT THE READER WILL GAIN: The identification of prognostic factors in rare tumors such as HIV-associated lymphomas is going to require the establishment of multi-institutional and cooperative group-supported tissue banks.
  • The rarity of primary effusion lymphomas and plasmablastic lymphomas of the oral cavity type makes large prospective studies difficult and challenges the feasibility of defining therapy specific for a given subpopulation of patients.
  • TAKE HOME MESSAGE: HIV-associated lymphomas still represent a relevant field of clinical research.
  • However, rituximab plus chemotherapy should be offered to the majority of patients with HIV infection and diffuse large B-cell lymphomas; and the feasibility of intensive aggressive chemotherapy regimens has been successfully tested in HIV-associated Burkitt's lymphomas.
  • [MeSH-major] HIV Infections / complications. HIV Infections / drug therapy. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / trends. Boronic Acids / therapeutic use. Bortezomib. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / drug therapy. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy. Pyrazines / therapeutic use. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726820.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Boronic Acids; 0 / Pyrazines; 0 / ofatumumab; 4F4X42SYQ6 / Rituximab; 69G8BD63PP / Bortezomib
  •  go-up   go-down


16. Lan K, Verma SC, Murakami M, Bajaj B, Robertson ES: Epstein-Barr Virus (EBV): infection, propagation, quantitation, and storage. Curr Protoc Microbiol; 2007 Aug;Chapter 14:Unit 14E.2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) was first reported as the etiological agent of Burkitt's lymphoma in 1964.
  • Since then, EBV has also been associated with nasopharyngeal carcinoma, which is highly prevalent in Southeast Asia, as well as infectious mononucleosis, complications of AIDS, and transplant-related B cell lymphomas.
  • This virus has further been linked with T cell lymphomas and Hodgkin's disease, establishing the concept of a wide spectrum of EBV-associated malignant disorders.
  • So far, there are a number of EBV-infected cell lines established that can be induced for production of infectious viral progeny and that facilitate the study of the mechanism of EBV-related infection, transformation, and oncogenesis.
  • This unit describes procedures for the preparation of EBV virion particles and in vitro infection of cells with EBV.
  • [MeSH-major] B-Lymphocytes / virology. Cell Transformation, Viral. Epithelial Cells / virology. Herpesvirus 4, Human. Virology / methods
  • [MeSH-minor] Animals. Cell Line. Cells, Cultured. Culture Media. Humans. Mice. Specimen Handling / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18770612.001).
  • [ISSN] 1934-8533
  • [Journal-full-title] Current protocols in microbiology
  • [ISO-abbreviation] Curr Protoc Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media
  •  go-up   go-down


17. Oksenhendler E, Gerard L, Dubreuil ML, Levy Y, Matheron S, Cazals-Hatem D, Chevret S, Clauvel JP: Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leuk Lymphoma; 2000 Sep;39(1-2):87-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
  • The purpose of the study was to evaluate the safety and long-term efficacy of an intensive chemotherapy regimen associated with G-CSF in HIV-associated non-Hodgkin's lymphoma (NHL).
  • The median CD4 cell count was 276 x 10(6)/l.
  • Nineteen tumors were of the Burkitt's type, 23 were large cells, 7 immunoblastic, and 3 anaplastic.
  • Twenty-five patients had stage IV disease (bone marrow involvement in 7, and central nervous system in 9).
  • Achievement of complete remission was strongly associated with survival.
  • In conclusion, it seems that in HIV-infected patients with NHL and a CD4 cell count above 100 x 10(6)/l, high complete remission rate and prolonged survival can be achieved with the intensive LNHIV-91 regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Actuarial Analysis. Adult. Bleomycin / administration & dosage. Bleomycin / toxicity. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Drug Evaluation. Etoposide / administration & dosage. Etoposide / toxicity. Female. Follow-Up Studies. Hospitalization. Humans. Male. Methotrexate / administration & dosage. Methotrexate / toxicity. Middle Aged. Prednisone / administration & dosage. Prednisone / toxicity. Recurrence. Survival Rate. Treatment Outcome. Vindesine / administration & dosage. Vindesine / toxicity

  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10975387.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; LNH 87 protocol
  •  go-up   go-down


18. Toomey NL, Deyev VV, Wood C, Boise LH, Scott D, Liu LH, Cabral L, Podack ER, Barber GN, Harrington WJ Jr: Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene; 2001 Oct 25;20(48):7029-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.
  • We have found that Azidothymidine (AZT) alone induces apoptosis in Epstein Barr Virus (EBV) positive Burkitt's lymphoma (BL) cells but requires interferon alpha (IFN-alpha) to induce apoptosis in Human Herpes Virus Type 8 (HHV-8) positive Primary Effusion Lymphomas (PEL).
  • Our analysis of a series of AIDS lymphomas revealed that IFN-alpha selectively induced very high levels of the Death Receptor (DR) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in HHV-8 positive PEL lines and primary tumor cells whereas little or no induction was observed in primary EBV+ AIDS lymphomas and EBV-Burkitt's lines.
  • AZT and IFN-alpha mediated apoptosis in PEL was blocked by stable overexpression of dominant negative Fas Associated Death Domain (FADD), decoy receptor 2 (DcR2), soluble TRAIL receptor fusion proteins (DR-4 and DR-5) and thymidine.
  • This novel antiviral approach to Primary Effusion lymphomas is targeted and may represent a highly effective and relatively non-toxic therapy.
  • [MeSH-major] Antiviral Agents / pharmacology. Apoptosis / drug effects. Arabidopsis Proteins. Immunologic Factors / pharmacology. Interferon-alpha / pharmacology. Lymphoma, AIDS-Related / therapy. Lymphoma, B-Cell / therapy. Membrane Glycoproteins / physiology. Tumor Necrosis Factor-alpha / physiology
  • [MeSH-minor] Antimetabolites, Antineoplastic / pharmacology. Antimetabolites, Antineoplastic / therapeutic use. Apoptosis Regulatory Proteins. Biopolymers. Cysteine Endopeptidases / metabolism. Drug Synergism. Enzyme Activation / drug effects. Epstein-Barr Virus Infections / complications. Etoposide / pharmacology. Fatty Acid Desaturases / biosynthesis. Fatty Acid Desaturases / genetics. Fatty Acid Desaturases / physiology. Gene Expression Regulation, Neoplastic / drug effects. Genes, bcl-2. HIV Infections / complications. Herpesviridae Infections / complications. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Humans. Immunocompromised Host. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand. Receptors, Tumor Necrosis Factor / biosynthesis. Receptors, Tumor Necrosis Factor / genetics. Receptors, Tumor Necrosis Factor / physiology. TNF-Related Apoptosis-Inducing Ligand. Thymidine / pharmacology. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism. Tumor Virus Infections / complications. Zidovudine / pharmacology. Zidovudine / therapeutic use. bcl-X Protein

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11704827.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA39201; United States / NCI NIH HHS / CA / CA77837; United States / NCI NIH HHS / CA / CA80228; United States / NCI NIH HHS / CA / CA82274
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antiviral Agents; 0 / Apoptosis Regulatory Proteins; 0 / Arabidopsis Proteins; 0 / BCL2L1 protein, human; 0 / Biopolymers; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human; 0 / TNFRSF10B protein, human; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / bcl-X Protein; 4B9XT59T7S / Zidovudine; 6PLQ3CP4P3 / Etoposide; EC 1.14.19.- / Fatty Acid Desaturases; EC 1.14.99.- / Fad7 protein, Arabidopsis; EC 3.4.22.- / Cysteine Endopeptidases; VC2W18DGKR / Thymidine
  •  go-up   go-down


19. Fenton SL, Luong QT, Sarafeim A, Mustard KJ, Pound J, Desmond JC, Gordon J, Drayson MT, Bunce CM: Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt's lymphoma cells and cell lines: potential for applying old drugs to a new disease. Leukemia; 2003 Mar;17(3):568-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt's lymphoma cells and cell lines: potential for applying old drugs to a new disease.
  • Current therapies for Burkitt's lymphoma (BL) utilise combined cytotoxic chemotherapy, but these treatments are not always available in areas where the disease is endemic and are also markedly less successful in AIDS-related BL.
  • We demonstrate here that combined fibrates and MPA exert powerful, antiproliferative actions against well-characterised Daudi, Raji and L3055 BL cell lines and primary BL cells.
  • Detailed studies in L3055 demonstrated that this activity was mediated by induced apoptosis and confirmed by observations that overexpression of the antiapoptotic genes bcl-2 or bcl-x(L) conferred significant protection against the drugs.
  • Importantly, since fibrates and MPA are inexpensive and stable with minimal-associated toxicities, we suggest that these drugs should be considered as adjuncts to currently available treatments for BL in endemic and AIDS-related disease.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Apoptosis / drug effects. Burkitt Lymphoma / pathology. Clofibric Acid / pharmacology. Hypolipidemic Agents / pharmacology. Medroxyprogesterone Acetate / pharmacology
  • [MeSH-minor] Cell Division / drug effects. Drug Interactions. Drug Therapy, Combination. Humans. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / pharmacology. Transduction, Genetic. Tumor Cells, Cultured. bcl-X Protein

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12646946.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / BCL2L1 protein, human; 0 / Hypolipidemic Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein; 53PF01Q249 / Clofibric Acid; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


20. Northup JK, Gadre SA, Ge Y, Lockhart LH, Velagaleti GV: Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition? Eur J Haematol; 2007 Feb;78(2):152-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first case is that of a lymph node sample from a 40-yr-old non-Hodgkin's lymphoma (NHL) patient sent for determination of disease progress.
  • Cytogenetic studies of lymph node showed multiple clonal abnormalities, most notably a der(18) from a t(14;18) which is associated with high-grade NHL.
  • After two cycles of chemotherapy with fludarabine, the patient did not show any clinical response, suggesting possible progression to high-grade lymphoma.
  • The second case is of a patient with a history of human immunodeficiency virus and blastic natural killer leukemia/lymphoma.
  • Hematologic studies of ascitic fluid classified the patient as having pleural effusion lymphoma whereas bone marrow analysis showed no malignancy.
  • Bone marrow cytogenetic studies showed multiple clonal abnormalities including a t(8;14), which is commonly associated with Burkitt's lymphoma (BL).
  • To our knowledge, this is the first case wherein a morphologically normal bone marrow showed presence of clonal abnormalities consistent with BL or Pleural effusion lymphoma.
  • After two cycles of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy, the patient's general condition and ascitis improved and she was discharged.
  • [MeSH-major] Burkitt Lymphoma / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Follicular / genetics. Lymphoma, Non-Hodgkin / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosomes, Human, Pair 12 / ultrastructure. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 18 / ultrastructure. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 8 / ultrastructure. Chromosomes, Human, X. Clone Cells / pathology. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm. Female. Genes, myc. Humans. Karyotyping. Lymph Nodes / pathology. Male. Mutagenesis, Insertional. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / pathology. Prednisone / administration & dosage. Rituximab. Trisomy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313561.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Sharma V: Current perspectives on cytokines for anti-retroviral therapy in AIDS related B-cell lymphomas. Curr Drug Targets Infect Disord; 2003 Jun;3(2):137-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current perspectives on cytokines for anti-retroviral therapy in AIDS related B-cell lymphomas.
  • The development of high-grade B-cell lymphoma in Acquired Immunodeficiency Syndrome (AIDS) patients is a relatively late manifestation induced by Human Immunodeficiency Virus-1 (HIV) infection and is considered to be an AIDS-defining condition.
  • Multiple, ongoing molecular and cytogenetic aberrations appear necessary for the development of AIDS-related lymphoma.
  • Studying a panel of human B-cell lines derived from patients with Burkitt's lymphoma (BL) and AIDS-associated Burkitt's lymphoma (AIDS-BL) we had described constitutive expression and secretion of large amounts of Interleukin-16 (IL-16), Macrophage Inflammatory Protein-1alpha (MIP-1alpha), Macrophage Inflammatory Protein-1beta (MIP-1beta), Interleukin-12 (IL-12), Interleukin-10 (IL-10), and Interleukin-7 (IL-7).
  • Some of these molecules serve to increase the infection and replication of HIV per se, and some others serve to induce a state of B-cell growth, activation, and differentiation.
  • This review attempts to delineate the complex mechanisms of viral, B-cell, oncogene, cytokine/cytokine receptor and transcription factor interactions that are involved in AIDS associated lymphomagenesis.
  • Unfolding the relationship between cytokines and the underlying mechanisms of the disease will not only help in understanding the pathophysiology but also will facilitate focusing on the development of new diagnostic and therapeutic strategies.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / immunology. Cytokines / immunology. Lymphoma, AIDS-Related / immunology
  • [MeSH-minor] B-Lymphocytes / metabolism. Chemokine CCL3. Chemokine CCL4. Chemokines / metabolism. Humans. Macrophage Inflammatory Proteins / metabolism. Receptors, Cytokine / metabolism. Transcription Factors / metabolism. Virus Replication / physiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12769791.001).
  • [ISSN] 1568-0053
  • [Journal-full-title] Current drug targets. Infectious disorders
  • [ISO-abbreviation] Curr Drug Targets Infect Disord
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chemokine CCL3; 0 / Chemokine CCL4; 0 / Chemokines; 0 / Cytokines; 0 / Macrophage Inflammatory Proteins; 0 / Receptors, Cytokine; 0 / Transcription Factors
  • [Number-of-references] 155
  •  go-up   go-down


22. Evens AM, Gordon LI: Burkitt's and Burkitt-like lymphoma. Curr Treat Options Oncol; 2002 Aug;3(4):291-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's and Burkitt-like lymphoma.
  • Burkitt's and Burkitt-like lymphoma (BL/BLL) are aggressive B-cell malignancies with a high proliferative rate that may be fatal within months if not treated promptly.
  • Furthermore, treatment of BL/BLL requires comprehensive supportive care to avoid disease-related complications such as acute renal failure secondary to tumor lysis syndrome.
  • Clinical trials have demonstrated that short duration, multi-agent, dose-intensive chemotherapy regimens combined with aggressive central nervous system therapy results in long-term survival rates in children and young adults near 70% to 80%, whereas long-term disease-free survival rates in older adults remains suboptimal at 15% to 25%.
  • Outcomes in HIV-associated BL/BLL are improved because of more effective chemotherapy regimens and enhanced HIV care.
  • Improved therapeutic strategies are warranted, such as integrating agents such as monoclonal antibodies to combination dose-intensive chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / therapy. Lymphoma, AIDS-Related / therapy

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Hematol. 2001 Oct;38(4 Suppl 10):13-21 [11694947.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2195-204 [8630379.001]
  • [Cites] N Engl J Med. 1977 Jul 14;297(2):75-80 [865579.001]
  • [Cites] Pediatr Nephrol. 1995 Apr;9(2):206-12 [7794722.001]
  • [Cites] Oncogene. 2000 Jul 13;19(30):3404-10 [10918597.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6281-92 [9774645.001]
  • [Cites] Am J Med. 1991 Mar;90(3):328-37 [2003515.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):9819-24 [11777933.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3707-21 [11054444.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2217-23 [8708710.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:77-81 [9187436.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):233-41 [1712662.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1252-61 [8648381.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] Ann Surg. 1982 Jul;196(1):82-6 [7092357.001]
  • [Cites] Blood. 1993 Apr 15;81(8):2003-6 [8471762.001]
  • [Cites] Blood. 1997 Nov 15;90(10):3844-52 [9354650.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B38-41 [11757704.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] Cancer. 1972 Dec;30(6):1534-40 [4641762.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3788-95 [9850023.001]
  • [Cites] J Pediatr. 1968 Mar;72(3):358-66 [5237793.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3857-9 [11739198.001]
  • [Cites] Gene. 2001 Oct 17;277(1-2):1-14 [11602341.001]
  • [Cites] Recent Results Cancer Res. 2002;159:149-53 [11785839.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1320-4 [11423264.001]
  • [Cites] Clin Lymphoma. 2000 Jun;1(1):46-54 [11707813.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):37-50 [11253608.001]
  • [Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]
  • [Cites] J Pediatr Surg. 1992 Feb;27(2):236-40 [1564624.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(12):1351-4 [11223978.001]
  • [Cites] Bone Marrow Transplant. 1995 Mar;15(3):353-9 [7599558.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 4):33-9; discussion 45-8 [9578060.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3601-6 [9817281.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3713-20 [11389007.001]
  • [Cites] Haematologica. 1996 Sep-Oct;81(5):442-9 [8952158.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):105-11 [11788631.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4014-22 [11600602.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):965-8 [11298592.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S91-5 [11587375.001]
  • [Cites] Oncology (Williston Park). 2001 May;15(5):629-39; discussion 639-40, 645-6 [11396357.001]
  • [Cites] Childs Nerv Syst. 1996 Apr;12 (4):210-4 [8739407.001]
  • [Cites] Crit Rev Oncol Hematol. 1986;4(3):221-48 [3513984.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4650-64 [11498788.001]
  • [Cites] Pediatr Hematol Oncol. 1997 Nov-Dec;14(6):555-61 [9383808.001]
  • [Cites] Semin Oncol Nurs. 1998 Nov;14(4):312-20 [9839344.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):680-9 [10931469.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):935-40 [8622042.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1696-702 [10738229.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1758-63 [10764437.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):809-12 [2185338.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2465-72 [8823324.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1071-2 [10744095.001]
  • [Cites] Curr Biol. 1997 Jun 1;7(6):357-65 [9197243.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3):322-34 [10864220.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):795-8 [10354149.001]
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1169-74 [2183052.001]
  • [Cites] Baillieres Clin Haematol. 1994 Jun;7(2):339-48 [7803905.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2281-5 [9649146.001]
  • [Cites] Ann Hematol. 1992 Nov;65(5):201-5 [1457577.001]
  • (PMID = 12074766.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 75
  •  go-up   go-down






Advertisement